Pharmaceutical composition containing glinides and vitamin B, and use of pharmaceutical composition

A technology of B vitamins and compositions, applied in the field of pharmacy, can solve the problems of lack of mechanism advantages, immune system disorders, weight gain, etc. for preventing or delaying diabetic complications, achieving suitable anti-diabetic drugs, improving hyperglycemia, and reducing vascular complications. The effect of the occurrence of the disease

Active Publication Date: 2014-02-26
SHENZHEN AUSA PHARM CO LTD +1
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, glinides also have some shortcomings: compared with traditional hypoglycemic drugs, glinides have a shorter history of clinical application, lack of mechanistic advantages in preventing or delaying diabetic complications, and lack of evidence-based medicine Research evidence; Glinides also have some adverse reactions, common ones are hypoglycemia and weight ga...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing glinides and vitamin B, and use of pharmaceutical composition
  • Pharmaceutical composition containing glinides and vitamin B, and use of pharmaceutical composition
  • Pharmaceutical composition containing glinides and vitamin B, and use of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1. Preparation of Compound Repaglinide / Folic Acid Tablets (1000 Tablets)

[0031]

[0032] Preparation method: Take the prescribed amount of folic acid and repaglinide and mix them uniformly according to the method of equal increase, and set aside; take the prescribed amount of microcrystalline cellulose, low-substituted hydroxypropyl cellulose (L-HPC), sodium carboxymethyl starch , fully mixed with the mixed powder of the raw material medicine, passed through a 80-mesh sieve, added an appropriate amount of 5% povidone 95% ethanol solution to make a soft material, granulated with a 20-mesh sieve, dried at 50°C for about 6 hours, granulated with a 20-mesh sieve, and controlled The water content of the granules is 2-3%, the dried granules are uniformly mixed with the prescribed amount of magnesium stearate, the intermediate is tested, and pressed into 1000 tablets. Pay attention to avoiding light during the preparation process, and the prepared tablets need to ...

Embodiment 2

[0033] Example 2. Preparation of Compound Nateglinide / Folic Acid Tablets (1000 Tablets)

[0034]

[0035] Preparation method: Take the prescribed amount of folic acid and nateglinide and mix them uniformly according to the method of equal increase, and set aside; weigh the prescribed amount of microcrystalline cellulose, lactose, crospovidone, and sodium carboxymethyl starch, and mix them with the raw materials Mix the powder well, pass through a 80 mesh sieve, add an appropriate amount of 10% polyvinylpyrrolidone solution to make a soft material, granulate with a 20 mesh sieve, dry at 50°C for about 6 hours, granulate with a 20 mesh sieve, and control the water content of the granules to 2-3 %, the dried granules are evenly mixed with the prescribed amount of glyceryl behenate and magnesium stearate, and the intermediates are tested, and pressed into 1000 tablets. Pay attention to avoiding light during the preparation process, and the prepared tablets need to be packed in ...

Embodiment 3

[0036] Example 3. Preparation of compound mitiglinide / 5-methyltetrahydrofolic acid tablets (1000 pieces)

[0037]

[0038] Preparation method: the auxiliary material is a direct pressing auxiliary material, which is dried for later use. The 5-methyltetrahydrofolate and microcrystalline cellulose of prescription quantity are mixed uniformly according to the method of equal increase to obtain mixed powder intermediate 1; microcrystalline cellulose, lactose and sodium carboxymethyl starch of remaining prescription quantity are weighed, Mix thoroughly with mitiglinide by the method of equal increments to obtain the mixed powder intermediate 2; mix the powder mixed intermediate 1 and the powder mixed intermediate 2 with the prescription amount of magnesium stearate according to the equal increment method to obtain The final mixed powder intermediate is tested and pressed into 1000 tablets. Pay attention to avoiding light during the preparation process, and the prepared tablets ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition containing glinide hypoglycemic medicines (glinides for short) and vitamin B, and use of the pharmaceutical composition. The pharmaceutical composition is prepared from one of therapeutically effective amounts of glinides and a medicinal precursor thereof, active metabolites or salts, one or more of therapeutically effective amounts of vitamins B, and pharmaceutically acceptable carriers, wherein the glinides mainly comprise repaglinide, nateglinide and mitiglinide; the content of the glinides is 0.5-120mg; the content of the vitamins B is 0.01-50mg. The invention also relates to use of the composition in preparation of a medicament for treating diabetes mellitus. The medicament prepared from the pharmaceutical composition provided by the invention has a more significant effect of preventing or delaying diabetes vascular lesion complications on the basis of effectively reducing blood sugar. In addition, a sufferer can be convenient to take medicine, and the compliance can be increased.

Description

technical field [0001] The invention relates to a pharmaceutical composition containing a glinide insulin secretion-stimulating agent (glinide for short) and B vitamins, belonging to the field of pharmacy. Background technique [0002] Diabetes mellitus is a common endocrine and metabolic disease characterized by chronic hyperglycemia accompanied by disturbances in sugar, fat and protein metabolism caused by insufficient insulin secretion and / or action defects. According to epidemiological surveys, the prevalence of diabetes in my country is as high as 9.7%, and it is estimated that the total number of adult diabetic patients in the country is 92.4 million [Yang W, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010; 362: 1090-1101]. In addition, according to the statistics of the International Diabetes Federation (IDF), there were 285 million people with diabetes worldwide in 2010, and it is estimated that nearly 500 million people worldwide will ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K31/519A61K31/451A61K31/714A61P3/10A61P9/10A61P17/02A61P9/00A61P13/12A61K31/198A61K31/4035
Inventor 徐希平张磊王存芳王滨燕
Owner SHENZHEN AUSA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap